HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

F Ciardiello Selected Research

Cyclic AMP-Dependent Protein Kinase Type I

8/2001Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
11/2000Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
6/2000Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


F Ciardiello Research Topics

Disease

48Neoplasms (Cancer)
01/2022 - 01/2000
24Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 03/2002
8Breast Neoplasms (Breast Cancer)
10/2018 - 01/2002
8Stomach Neoplasms (Stomach Cancer)
06/2014 - 05/2005
7Colonic Neoplasms (Colon Cancer)
03/2008 - 05/2000
4Neoplasm Metastasis (Metastasis)
01/2018 - 07/2003
4Disease Progression
01/2018 - 01/2011
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2012 - 03/2006
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2018 - 06/2007
3Carcinoma (Carcinomatosis)
07/2001 - 11/2000
2Adenocarcinoma
01/2018 - 06/2014
2Pathologic Complete Response
06/2014 - 02/2012
2Lung Neoplasms (Lung Cancer)
07/2011 - 03/2006
2Ovarian Neoplasms (Ovarian Cancer)
03/2002 - 11/2000
1Rectal Neoplasms (Rectal Cancer)
05/2021
1Melanoma (Melanoma, Malignant)
09/2018
1Fatigue
01/2018
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
10/2015
1Hand-Foot Syndrome
10/2015
1Renal Cell Carcinoma (Grawitz Tumor)
09/2014
1Neoplasm Micrometastasis
09/2014

Drug/Important Bio-Agent (IBA)

22ErbB Receptors (EGF Receptor)IBA
01/2020 - 01/2000
20Cetuximab (Erbitux)FDA Link
01/2022 - 01/2000
12Gefitinib (Iressa)FDA Link
07/2011 - 01/2000
9Monoclonal AntibodiesIBA
09/2014 - 09/2000
8Biological ProductsIBA
10/2018 - 06/2000
8Pharmaceutical PreparationsIBA
02/2015 - 05/2000
8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2011 - 09/2000
7Antisense OligonucleotidesIBA
12/2001 - 03/2000
6Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2016 - 05/2000
6Tyrosine Kinase InhibitorsIBA
07/2011 - 05/2000
6Paclitaxel (Taxol)FDA LinkGeneric
01/2011 - 05/2000
6Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2006 - 05/2000
5Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
05/2012 - 03/2000
4Leucovorin (Folinic Acid)FDA Link
01/2016 - 05/2005
4Fluorouracil (Carac)FDA LinkGeneric
01/2016 - 05/2005
4Erlotinib Hydrochloride (CP 358,774)FDA Link
07/2011 - 10/2001
4Immunoglobulin G (IgG)IBA
01/2011 - 01/2000
4Cisplatin (Platino)FDA LinkGeneric
11/2010 - 05/2000
4Proteins (Proteins, Gene)FDA Link
08/2008 - 06/2000
4Docetaxel (Taxotere)FDA Link
10/2006 - 05/2000
4AgarIBA
08/2001 - 05/2000
4OligonucleotidesIBA
08/2001 - 09/2000
4Transforming Growth Factor alpha (TGF-alpha)IBA
05/2001 - 05/2000
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2019 - 07/2011
3GemcitabineFDA Link
01/2018 - 06/2007
3AntibodiesIBA
08/2017 - 05/2005
3Sorafenib (BAY 43-9006)FDA Link
10/2015 - 07/2011
3Topotecan (Hycamtin)FDA LinkGeneric
03/2002 - 05/2000
3Cyclic AMP-Dependent Protein Kinase Type IIBA
08/2001 - 06/2000
2encorafenibIBA
01/2022 - 12/2021
2Sunitinib (Sutent)FDA Link
10/2015 - 09/2014
2EverolimusFDA Link
09/2014 - 03/2008
2vandetanib (ZD6474)IBA
07/2011 - 05/2005
2Trastuzumab (Herceptin)FDA Link
11/2010 - 01/2002
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
10/2009 - 03/2006
2Etoposide (VP 16)FDA LinkGeneric
08/2007 - 05/2000
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2007 - 05/2000
2PlatinumIBA
06/2007 - 05/2005
2taxaneIBA
05/2005 - 12/2001
2Epidermal Growth Factor (EGF)IBA
05/2005 - 11/2000
2Carboplatin (JM8)FDA LinkGeneric
05/2005 - 05/2000
2DNA (Deoxyribonucleic Acid)IBA
01/2002 - 08/2001
2Doxorubicin (Adriamycin)FDA LinkGeneric
07/2001 - 05/2000
2Cytostatic AgentsIBA
05/2001 - 09/2000
2Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
05/2001 - 09/2000
1binimetinibIBA
01/2022
1Trinitrotoluene (TNT)IBA
05/2021
1Immune Checkpoint InhibitorsIBA
12/2019
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
10/2018
1ipatasertibIBA
10/2018
12- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA
10/2018
1Biomarkers (Surrogate Marker)IBA
09/2018
1InterferonsIBA
09/2018
1IpilimumabIBA
09/2018
1130-nm albumin-bound paclitaxelIBA
01/2018
1BilirubinIBA
01/2018
1nintedanibIBA
01/2018
1Irinotecan (Camptosar)FDA LinkGeneric
01/2016
1regorafenibIBA
10/2015
1pazopanibFDA Link
10/2015
1cabozantinibIBA
10/2015
1Axitinib (AG 013736)IBA
10/2015
1N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA
06/2015
1Mitogen-Activated Protein KinasesIBA
06/2015
1sonidegibIBA
09/2014
1Growth Factor ReceptorsIBA
09/2014

Therapy/Procedure

25Therapeutics
01/2022 - 10/2001
16Drug Therapy (Chemotherapy)
08/2017 - 10/2001
10Radiotherapy
05/2021 - 11/2000
5Chemoradiotherapy
05/2021 - 06/2007
5Aftercare (After-Treatment)
12/2001 - 09/2000
3Adjuvant Chemotherapy
08/2007 - 05/2005
2Precision Medicine
02/2015 - 09/2014
2Oral Administration
12/2001 - 06/2000
1Neoadjuvant Therapy
05/2021
1Molecular Targeted Therapy
09/2018
1Immunotherapy
09/2018
1Stents
01/2018
1Conformal Radiotherapy
06/2014